NorthStrive Fund II LP (“NorthStrive Fund”), a subsidiary of NorthStrive Companies Inc., today issued an open letter to the Board of Directors and shareholders of Bluejay Diagnostics, Inc. (“Bluejay” ...

Antwan Lofton, Vice President for Duke Human Resources, said the Foundational Skills Program is designed to open doors for ...

Cinclus Pharma is a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases -- Claret Capital Partners providing growth funding of up to ...

Claret Capital Partners invests €28M in Cinclus Pharma Cinclus Pharma is a late-stage clinical pharmaceutical company ...

Core Economic Terms of $6.0 Million Financing Remain Unchanged Jupiter Neurosciences, Inc. (NASDAQ:JUNS)That alignment ...

MBX Biosciences (NASDAQ:MBX) executives outlined key clinical and development milestones expected through 2026 during an Oppenheimer life sciences team event featuring CEO Kent Hawryluk and Chief ...

Q4 2025 earnings call: soquelitinib trial progress, Phase III PTCL/Phase II AD timelines, and cash runway to Q2 2028—read now.

AMT-130 Huntington’s gene therapy data, FDA Phase III sham-trial push, cash runway, and 2026 catalysts—read now.

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

March is MS Awareness Month, a nationwide campaign raising awareness about the chronic disease that affects 2.9 million people worldwide. IMSMP and Tisch MSRCNY serve as an example of the laboratory ...

The private placement is led by Coastlands Capital, with participation from Janus Henderson Investors, along with Logos Capital and Kalehua Capital, for total gross proceeds in the initial closing of ...

Q4 2025 Management View CEO Joseph Payne provided an update on the ARCT-032 and ARCT-810 programs, stating the ARCT-032 Phase II trial is progressing with higher dose testing at 15 milligrams in 4 ...